GILD

Gilead Sciences

D
GILD
USD
5.42
(5.9196%)
مفتوح الان
407,370.00
حجم التداول
3.95
الربح لكل سهم
3.66
العائد الربحي
117.902
P/E
120,303,584,787.03
حجم السوق
اليوم
5.6466%
1 اسبوع
9.846%
1 شهر
14.365%
6 اشهر
49.344%
12 اشهر
18.571%
بداية السنة
19.405%
كل الوقت
0%
avatar
هشام منسي
منذ أسبوع
30.10.2024 14:50
جيلاد ساينسز: الابتكار في العلاج وإدارة الأرباح 2024/10/30

Title:
Gilead Sciences

Sector:
Healthcare
Industry:
Drug Manufacturers - General
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
هل تحتاج مساعدة او لديك استفسار؟